A Johnson Pharmaceuticals (03692.HK) target price from Nomura has been raised by 2% to 18.36 Hong Kong dollars, reflecting a downside of 3.2%, maintaining a neutral rating. The bank expects a 0.5% decline in revenue in the second half of 2024, and profits will decrease by 35% annually. The bank has lowered its revenue and profit forecasts for the 2024 fiscal year by 0.6% and 4.2%, respectively, and raised its revenue and profit forecasts for the 2025 fiscal year by 4.5% and 1.8%, considering factors such as cooperation revenue from authorizing HS-10535 (oral GLP-1 asset) to MSD and sales performance exceeding expectations.
Ver original
Esta página pode conter conteúdos de terceiros, que são fornecidos apenas para fins informativos (sem representações/garantias) e não devem ser considerados como uma aprovação dos seus pontos de vista pela Gate, nem como aconselhamento financeiro ou profissional. Consulte a Declaração de exoneração de responsabilidade para obter mais informações.
Nomura Upgrades Johnson Pharmaceutical's target price by 2% to 18.36 HKD, maintaining a neutral rating.
A Johnson Pharmaceuticals (03692.HK) target price from Nomura has been raised by 2% to 18.36 Hong Kong dollars, reflecting a downside of 3.2%, maintaining a neutral rating. The bank expects a 0.5% decline in revenue in the second half of 2024, and profits will decrease by 35% annually. The bank has lowered its revenue and profit forecasts for the 2024 fiscal year by 0.6% and 4.2%, respectively, and raised its revenue and profit forecasts for the 2025 fiscal year by 4.5% and 1.8%, considering factors such as cooperation revenue from authorizing HS-10535 (oral GLP-1 asset) to MSD and sales performance exceeding expectations.